Fig. 2From: Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional studyEQ-5D-5L results by domain. *P < 0.05, †P < 0.01 for the difference in LS means between G551D/IVA and F508del/SOC groups. EQ-5D-5L EuroQol 5-dimensions 5-level questionnaire, IVA ivacaftor, SOC standard of careBack to article page